CFCThe Compounder Score
CTSO logo

CTSO — Cytosorbents Corporation

Medical DevicesHealthcare

$4.87

$-0.50 (-9.31%)

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications.

Market Cap

$15.35M

Forward P/E

Infinityx

52-Week Range

N/A

CTSO Price History

No cached price history available for this ticker yet.

Revenue vs. Net Income

$37.1M

Revenue · FY2025

Annual. Net margin is shown under each year.

RevenueNet income (green profit, red loss)

Free Cash Flow

-$12.9M

FCF · FY2025

Annual. FCF margin is shown under each year.

Return on Capital Employed (ROCE)

-17.4%

ROCE · FY2025

Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.

Total Assets vs. Total Liabilities

1.2x

Assets ÷ liabilities · FY2025

Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.

Total assetsTotal liabilities

CapEx as % of Revenue

1.3%

CapEx · FY2025

Annual. Green at or under the 5% maximum target, red above it.

Shares Outstanding

+14.3%

Dilution · FY2025

Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).